Precept Management’s Regenxbio RGNX Stock Holding History

Precept Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,000	Closed	-$516K	–	92
2020 Q2	$516K	Hold	14,000	–	–	0.1%	72
2020 Q1	$453K	Buy	+14,000	New	+$583K	0.06%	98

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Precept Management's RGNX Position: Q3 2020 in Review

Precept Management sold out of Regenxbio (RGNX) in Q3 2020, closing a stake of 14,000 shares — an estimated $516K sold.

Precept Management first reported a position in RGNX in Q1 2020 and held it in 2 quarters. The position peaked at $516K in Q2 2020. 166 funds tracked by Wall St. Rank hold RGNX as of Q3 2020.

Precept Management reported no remaining Regenxbio position as of Q3 2020 after selling out during the quarter.
Precept Management sold 14,000 Regenxbio shares in Q3 2020, an estimated $516K.
Precept Management first reported a position in Regenxbio in Q1 2020 and held it in 2 quarters.
Precept Management's Regenxbio position peaked at $516K in Q2 2020.
166 funds tracked by Wall St. Rank held Regenxbio as of Q3 2020.

Based on Precept Management's 13F filing for Q3 2020, filed 16 Nov 2020.